Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings.
ACPA
Autoimmunity
Immunoglobulin
Rheumatoid arthritis
Journal
Clinical reviews in allergy & immunology
ISSN: 1559-0267
Titre abrégé: Clin Rev Allergy Immunol
Pays: United States
ID NLM: 9504368
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
accepted:
24
08
2021
pubmed:
9
9
2021
medline:
14
9
2022
entrez:
8
9
2021
Statut:
ppublish
Résumé
Autoantibodies represent a hallmark of rheumatoid arthritis (RA), with the rheumatoid factor (RF) and antibodies against citrullinated proteins (ACPA) being the most acknowledged ones. RA patients who are positive for RF and/or ACPA ("seropositive") in general display a different etiology and disease course compared to so-called "seronegative" patients. Still, the seronegative patient population is very heterogeneous and not well characterized. Due to the identification of new autoantibodies and advancements in the diagnosis of rheumatic diseases in the last years, the group of seronegative patients is constantly shrinking. Aside from antibodies towards various post-translational modifications, recent studies describe autoantibodies targeting some native proteins, further broadening the spectrum of recognized antigens. Next to the detection of new autoantibody groups, much research has been done to answer the question if and how autoantibodies contribute to the pathogenesis of RA. Since autoantibodies can be detected years prior to RA onset, it is a matter of debate whether their presence alone is sufficient to trigger the disease. Nevertheless, there is gathering evidence of direct autoantibody effector functions, such as stimulation of osteoclastogenesis and synovial fibroblast migration in in vitro experiments. In addition, autoantibody positive patients display a worse clinical course and stronger radiographic progression. In this review, we discuss current findings regarding different autoantibody types, the underlying disease-driving mechanisms, the role of Fab and Fc glycosylation and clinical implications.
Identifiants
pubmed: 34495490
doi: 10.1007/s12016-021-08890-1
pii: 10.1007/s12016-021-08890-1
pmc: PMC9464122
doi:
Substances chimiques
Autoantibodies
0
Rheumatoid Factor
9009-79-4
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
138-151Subventions
Organisme : deutsche forschungsgemeinschaft
ID : FOR2886 PANDORA
Organisme : deutsche forschungsgemeinschaft
ID : SPP1468-IMMUNOBONE
Organisme : innovative medicines initiative
ID : RTCure grant (no. 777357)
Organisme : bundesministerium für bildung und forschung
ID : MASCARA
Informations de copyright
© 2021. The Author(s).
Références
Landré Beauvais AJ (2001) The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800. Jt Bone Spine 68:130–143. https://doi.org/10.1016/S1297-319X(00)00247-5
doi: 10.1016/S1297-319X(00)00247-5
Entezami P, Fox DA, Clapham PJ, Chung KC (2011) Historical perspective on the etiology of rheumatoid arthritis. Hand Clin 27:1–10. https://doi.org/10.1016/j.hcl.2010.09.006
doi: 10.1016/j.hcl.2010.09.006
Scherer HU, Huizinga TWJ, Krönke G, Schett G, Toes REM (2018) The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nat Rev Rheumatol 14:157–169. https://doi.org/10.1038/nrrheum.2018.10
doi: 10.1038/nrrheum.2018.10
Franklin EC, Holman HR, Müller-Eberhard HJ, Kunkel HG (1957) An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J Exp Med 105:425–438. https://doi.org/10.1084/jem.105.5.425
doi: 10.1084/jem.105.5.425
Aggarwal R, Liao K, Nair R, Ringold S, Costenbader KH (2009) Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Care Res 61:1472–1483. https://doi.org/10.1002/art.24827
doi: 10.1002/art.24827
Nienhuis RLF, Mandema E, Smids C (1964) New serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Ann Rheum Dis 23:302–305. https://doi.org/10.1136/ard.23.4.302
doi: 10.1136/ard.23.4.302
Van Venrooij WJ, Pruijn GJM (2014) How citrullination invaded rheumatoid arthritis research. Arthritis Res Ther 16:1–5. https://doi.org/10.1186/ar4458
doi: 10.1186/ar4458
de Brito RS, Baldo DC, Andrade LEC (2019) Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Adv Rheumatol 59:2. https://doi.org/10.1186/s42358-018-0042-8
doi: 10.1186/s42358-018-0042-8
Reed E, Hedström AK, Hansson M, Mathsson-Alm L, Brynedal B, Saevarsdottir S, Cornillet M, Jakobsson PJ, Holmdahl R, Skriner K, Serre G, Alfredsson L, Rönnelid J, Lundberg K (2020) Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity. Arthritis Res Ther 22:1–11. https://doi.org/10.1186/s13075-020-02191-2
doi: 10.1186/s13075-020-02191-2
Li K, Mo W, Wu L, Wu X, Luo C, Xiao X, Jia X, Yang H, Fei Y, Chen H, Zhang F, Li Y, Zhao L, Zhang X (2021) Novel autoantibodies identified in ACPA-negative rheumatoid arthritis. Ann Rheum Dis 80:739–747. https://doi.org/10.1136/annrheumdis-2020-218460
doi: 10.1136/annrheumdis-2020-218460
Paalanen K, Puolakka K, Nikiphorou E, Hannonen P, Sokka T (2020) Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study. Rheumatology (Oxford) 60:2391–2395. https://doi.org/10.1093/rheumatology/keaa623
doi: 10.1093/rheumatology/keaa623
Schellekens GA, De Jong BAW, Van Den Hoogen FHJ, Van De Putte LBA, Van Venrooij WJ (2015) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Immunol 195:8–16. https://doi.org/10.1172/JCI1316
doi: 10.1172/JCI1316
Szekanecz Z, Szabó Z, Zeher M, Soós L, Dankó K, Horváth I, Lakos G (2013) Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunol Res 56:439–443. https://doi.org/10.1007/s12026-013-8425-8
doi: 10.1007/s12026-013-8425-8
Di Matteo A, Mankia K, Duquenne L, Mahler M, Corscadden D, Mbara K, Garcia-Montoya L, Nam JL, Emery P (2020) Third-generation anti–cyclic citrullinated peptide antibodies improve prediction of clinical arthritis in individuals at risk of rheumatoid arthritis. Arthritis Rheumatol 72:1820–1828. https://doi.org/10.1002/art.41402
doi: 10.1002/art.41402
Curran AM, Naik P, Giles JT, Darrah E (2020) PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Nat Rev Rheumatol 16:301–315. https://doi.org/10.1038/s41584-020-0409-1
doi: 10.1038/s41584-020-0409-1
Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y (2010) PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med 207:1853–1862. https://doi.org/10.1084/jem.20100239
doi: 10.1084/jem.20100239
Liang B, Ge C, Lönnblom E, Lin X, Feng H, Xiao L, Bai J, Ayoglu B, Nilsson P, Nandakumar KS, Zhao M, Holmdahl R (2019) The autoantibody response to cyclic citrullinated collagen type II peptides in rheumatoid arthritis. Rheumatology (Oxford) 58:1623–1633. https://doi.org/10.1093/rheumatology/kez073
doi: 10.1093/rheumatology/kez073
Joshua V, Schobers L, Titcombe PJ, Israelsson L, Rönnelid J, Hansson M, Catrina AI, Pruijn GJM, Malmström V (2016) Antibody responses to de novo identified citrullinated fibrinogen peptides in rheumatoid arthritis and visualization of the corresponding B cells. Arthritis Res Ther 18:1–9. https://doi.org/10.1186/s13075-016-1181-0
doi: 10.1186/s13075-016-1181-0
Ge C, Holmdahl R (2019) The structure, specificity and function of anti-citrullinated protein antibodies. Nature Rev Rheumatol 15:503–508. https://doi.org/10.1038/s41584-019-0244-4
Lundberg K, Kinloch A, Fisher BA, Wegner N, Wait R, Charles P, Mikuls TR, Venables PJ (2008) Antibodies to Citrullinated-Enolase Peptide 1 Are Specific for Rheumatoid Arthritis and Cross-React With Bacterial Enolase. Arthritis Rheum 58:3009–3019. https://doi.org/10.1002/art.23936
doi: 10.1002/art.23936
Shoda H, Fujio K, Shibuya M, Okamura T, Sumitomo S, Okamoto A, Sawada T, Yamamoto K (2011) Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis. Arthritis Res Ther 13:191. https://doi.org/10.1186/ar3520
doi: 10.1186/ar3520
Haag S, Schneider N, Mason DE, Tuncel J, Andersson IE, Peters EC, Burkhardt H, Holmdahl R (2014) Identification of new citrulline-specific autoantibodies, which bind to human arthritic cartilage, by mass spectrometric analysis of citrullinated type II collagen. Arthritis Rheumatol 66:1440–1449. https://doi.org/10.1002/art.38383
doi: 10.1002/art.38383
Burkhardt H, Sehnert B, Bockermann R, Engström Å, Kalden JR, Holmdahl R (2005) Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 35:1643–1652. https://doi.org/10.1002/eji.200526000
doi: 10.1002/eji.200526000
Lo KC, Sullivan E, Bannen RM, Jin H, Rowe M, Li H, Pinapati RS, Cartwright AJ, Tan JC, Patel J, Keystone EC, Siminovitch KA (2020) Comprehensive profiling of the rheumatoid arthritis antibody repertoire. Arthritis Rheumatol 72:242–250. https://doi.org/10.1002/art.41089
doi: 10.1002/art.41089
Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, Edison JD, Gilliland WR, Tibshirani RJ, Norris JM, Holers VM, Robinson WH (2012) Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 7:1–9. https://doi.org/10.1371/journal.pone.0035296
doi: 10.1371/journal.pone.0035296
Steen J, Forsström B, Sahlström P, Odowd V et al (2019) Recognition of amino acid motifs, rather than specific proteins, by human plasma cell-derived monoclonal antibodies to posttranslationally modified proteins in rheumatoid arthritis. Arthritis Rheumatol 71:196–209. https://doi.org/10.1002/art.40699
doi: 10.1002/art.40699
Ge C, Xu B, Liang B, Lönnblom E, Lundström SL, Zubarev RA, Ayoglu B, Nilsson P, Skogh T, Kastbom A, Malmström V, Klareskog L, Toes REM, Rispens T, Dobritzsch D, Holmdahl R (2019) Structural basis of Cross-Reactivity of Anti-Citrullinated protein antibodies. Arthritis Rheumatol 71:210–221. https://doi.org/10.1002/art.40698
doi: 10.1002/art.40698
Sahlström P, Hansson M, Steen J, Amara K, Titcombe PJ, Forsström B, Stålesen R, Israelsson L, Piccoli L, Lundberg K, Klareskog L, Mueller DL, Catrina AI, Skriner K, Malmström V, Grönwall C (2020) Different hierarchies of anti–modified protein autoantibody reactivities in rheumatoid arthritis. Arthritis Rheumatol 72:1643–1657. https://doi.org/10.1002/art.41385
doi: 10.1002/art.41385
Ioan-Facsinay A, El-Bannoudi H, Scherer HU, Van Der Woude D, Ménard HA, Lora M, Trouw LA, Huizinga TWJ, Toes REM (2011) Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 70:188–193. https://doi.org/10.1136/ard.2010.131102
doi: 10.1136/ard.2010.131102
van de Stadt LA, van Schouwenburg PA, Bryde S, Kruithof S, van Schaardenburg D, Hamann D, Wolbink G, Rispens T (2013) Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patterns. Rheumatol (Oxford) 52:631–635. https://doi.org/10.1093/rheumatology/kes371
doi: 10.1093/rheumatology/kes371
Thiele GM, Duryee MJ, Anderson DR et al (2015) Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol 67:645–655. https://doi.org/10.1002/art.38969
doi: 10.1002/art.38969
Kissel T, Reijm S, Slot LM et al (2020) Antibodies and B cells recognising citrullinated proteins display a broad cross- reactivity towards other post- translational modifications. Ann Rheum Dis 79:472–480. https://doi.org/10.1136/annrheumdis-2019-216499
doi: 10.1136/annrheumdis-2019-216499
Shi J, Willemze A, Janssen GMC, Van Veelen PA, Drijfhout JW, Cerami A, Huizinga TWJ, Trouw LA, Toes RE (2013) Recognition of citrullinated and carbamylated proteins by human antibodies: Specificity, cross-reactivity and the “AMC-Senshu” method. Ann Rheum Dis 72:148–150. https://doi.org/10.1136/annrheumdis-2012-201559
doi: 10.1136/annrheumdis-2012-201559
Trouw LA, Rispens T, Toes REM (2017) Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. Nat Rev Rheumatol 13:331–339. https://doi.org/10.1038/nrrheum.2017.15
doi: 10.1038/nrrheum.2017.15
Volkov M, van Schie KA, van der Woude D (2020) Autoantibodies and B cells: the ABC of rheumatoid arthritis pathophysiology. Immunol Rev 294:148–163. https://doi.org/10.1111/imr.12829
doi: 10.1111/imr.12829
Shi J, van Veelen PA, Mahler M, Janssen GMC, Drijfhout JW, Huizinga TWJ, Toes REM, Trouw LA (2014) Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev 13:225–230. https://doi.org/10.1016/j.autrev.2013.10.008
doi: 10.1016/j.autrev.2013.10.008
Shi J, Knevel R, Suwannalai P, Van Der Linden MP, Janssen GMC, Van Veelen PA, Levarht NEW, Van Der Helm-van Mil AHM, Cerami A, Huizinga TWJ, Toes REM, Trouw LA (2011) Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 108:17372–17377. https://doi.org/10.1073/pnas.1114465108
doi: 10.1073/pnas.1114465108
Reed E, Jiang X, Kharlamova N, Ytterberg AJ, Catrina AI, Israelsson L, Mathsson-Alm L, Hansson M, Alfredsson L, Rönnelid J, Lundberg K (2016) Antibodies to carbamylated α-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies. Arthritis Res Ther 18:1–9. https://doi.org/10.1186/s13075-016-1001-6
doi: 10.1186/s13075-016-1001-6
Lloyd KA, Wigerblad G, Sahlström P et al (2019) Differential ACPA binding to nuclear antigens reveals a PAD-independent pathway and a distinct subset of acetylation cross-reactive autoantibodies in rheumatoid arthritis. Front Immunol 9:3033. https://doi.org/10.3389/fimmu.2018.03033
doi: 10.3389/fimmu.2018.03033
Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, Reynolds WF, Topol EJ, DiDonato JA, Hazen SL (2007) Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 13:1176–1184. https://doi.org/10.1038/nm1637
doi: 10.1038/nm1637
Castellanos-Moreira R, Rodríguez-García SC, Gomara MJ, Ruiz-Esquide V, Cuervo A, Casafont-Solé I, Ramírez J, Holgado S, Gómez-Puerta JA, Cañete JD, Haro I, Sanmarti R (2020) Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: Evidence of a new autoantibody linked to interstitial lung disease. Ann Rheum Dis 79:587–594. https://doi.org/10.1136/annrheumdis-2019-216709
doi: 10.1136/annrheumdis-2019-216709
Mikuls TR, Duryee MJ, Rahman R et al (2017) Enrichment of malondialdehyde-acetaldehyde antibody in the rheumatoid arthritis joint. Rheumatology (Oxford) 56:1794–1803. https://doi.org/10.1093/rheumatology/kex212
doi: 10.1093/rheumatology/kex212
Grönwall C, Amara K, Hardt U et al (2017) Autoreactivity to malondialdehyde-modifications in rheumatoid arthritis is linked to disease activity and synovial pathogenesis. J Autoimmun 84:29–45. https://doi.org/10.1016/j.jaut.2017.06.004
doi: 10.1016/j.jaut.2017.06.004
England BR, Duryee MJ, Roul P, Mahajan TD, Singh N, Poole JA, Ascherman DP, Caplan L, Demoruelle MK, Deane KD, Klassen LW, Thiele GM, Mikuls TR (2019) Malondialdehyde-Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol 71:1483–1493. https://doi.org/10.1002/art.40900
doi: 10.1002/art.40900
Juarez M, Bang H, Hammar F, Reimer U, Dyke B, Sahbudin I, Buckley CD, Fisher B, Filer A, Raza K (2016) Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis. Ann Rheum Dis 75:1099–1107. https://doi.org/10.1136/annrheumdis-2014-206785
doi: 10.1136/annrheumdis-2014-206785
Rodriguez-Martínez L, Bang H, Regueiro C et al (2020) Improved classification of rheumatoid arthritis with a score including anti-acetylated ornithine antibodies. Sci Rep 10:1–10. https://doi.org/10.1038/s41598-020-73919-y
doi: 10.1038/s41598-020-73919-y
Regueiro C, Nuño L, Ortiz AM, Peiteado D, Villalba A, Pascual-Salcedo D, Martínez-Feito A, González-Alvaro I, Balsa A, González A (2017) Value of measuring anti-carbamylated protein antibodies for classification on early arthritis patients. Sci Rep 7:1–8. https://doi.org/10.1038/s41598-017-09657-5
doi: 10.1038/s41598-017-09657-5
Pietrogrande M, Corona M, Milani S, Rosti A, Ramella M, Tordato G (1995) Relationship between rheumatoid factor and the immune response against hepatitis C virus in essential mixed cryoglobulinemia. Clin Exp Rheumatol 13(Suppl 1):109–113
Janssen KMJ, Hop H, Vissink A, Dijkstra G, de Smit MJ, Brouwer E, Westra J (2020) Levels of anti-citrullinated protein antibodies and rheumatoid factor, including iga isotypes, and articular manifestations in ulcerative colitis and crohn’s disease. Int J Environ Res Public Health 17:1–10. https://doi.org/10.3390/ijerph17218054
doi: 10.3390/ijerph17218054
Maślińska M, Mańczak M, Kwiatkowska B, Ramsperger V, Shen L, Suresh L (2021) IgA immunoglobulin isotype of rheumatoid factor in primary Sjögren’s syndrome. Rheumatol Int 41:643–649. https://doi.org/10.1007/s00296-020-04782-3
doi: 10.1007/s00296-020-04782-3
Ugolini A, Nuti M (2021) Rheumatoid factor: A novel determiner in cancer history. Cancers (Basel) 13:1–9. https://doi.org/10.3390/cancers13040591
doi: 10.3390/cancers13040591
Ingegnoli F, Castelli R, Gualtierotti R (2013) Rheumatoid factors: Clinical applications. Dis Markers 35:727–734. https://doi.org/10.1155/2013/726598
doi: 10.1155/2013/726598
Bassi N, Ghirardello A, Blank M, Zampieri S, Sarzi-Puttini P, Mantovani A, Shoenfeld Y, Doria A (2010) IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis 69:1704–1710. https://doi.org/10.1136/ard.2009.117804
doi: 10.1136/ard.2009.117804
Augusto JF, Poli C, Beauvillain C, Subra JF, Jaillon S, Renier G, Chevailler A, Puéchal X, Delneste Y, Jeannin P (2017) Anti-pentraxin antibodies in autoimmune systemic diseases: Focus on anti-pentraxin-3 autoantibodies. Int Rev Immunol 36:145–153. https://doi.org/10.1080/08830185.2017.1284210
doi: 10.1080/08830185.2017.1284210
Poulsen TBG, Damgaard D, Jørgensen MM, Senolt L, Blackburn JM, Nielsen CH, Stensballe A (2020) Identification of novel native autoantigens in rheumatoid arthritis. Biomedicines 8:1–13. https://doi.org/10.3390/BIOMEDICINES8060141
doi: 10.3390/BIOMEDICINES8060141
Bhattacharjee M, Balakrishnan L, Renuse S, Advani J, Goel R, Sathe G, Keshava Prasad TS, Nair B, Jois R, Shankar S, Pandey A (2016) Synovial fluid proteome in rheumatoid arthritis. Clin Proteomics 13:1–11. https://doi.org/10.1186/s12014-016-9113-1
doi: 10.1186/s12014-016-9113-1
Pratesi F, Petit Teixeira E, Sidney J, Michou L, Puxeddu I, Sette A, Cornelis F, Migliorini P (2013) HLA shared epitope and ACPA: Just a marker or an active player? Autoimmun Rev 12:1182–1187. https://doi.org/10.1016/j.autrev.2013.08.002
doi: 10.1016/j.autrev.2013.08.002
Huizinga TWJ, Amos CI, Van Der Helm-Van Mil AHM et al (2005) Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 52:3433–3438. https://doi.org/10.1002/art.21385
doi: 10.1002/art.21385
Terao C, Ohmura K, Ikari K, Kawaguchi T, Takahashi M, Setoh K, Nakayama T, Kosugi S, Sekine A, Tabara Y, Taniguchi A, Momohara S, Yamanaka H, Yamada R, Matsuda F, Mimori T (2014) Effects of smoking and shared epitope on the production of anti-citrullinated peptide antibody in a Japanese adult population. Arthritis Care Res 66:1818–1827. https://doi.org/10.1002/acr.22385
doi: 10.1002/acr.22385
Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E (2003) Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 171:538–541. https://doi.org/10.4049/jimmunol.171.2.538
doi: 10.4049/jimmunol.171.2.538
Ting YT, Petersen J, Ramarathinam SH, Scally SW, Loh KL, Thomas R, Suri A, Baker DG, Purcell AW, Reid HH, Rossjohn J (2018) The interplay between citrullination and HLA-DRB1 polymorphism in shaping peptide binding hierarchies in rheumatoid arthritis. J Biol Chem 293:3236–3251. https://doi.org/10.1074/jbc.RA117.001013
doi: 10.1074/jbc.RA117.001013
Auger I, Sebbag M, Vincent C, Balandraud N, Guis S, Nogueira L, Svensson B, Cantagrel A, Serre G, Roudier J (2005) Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum 52:3424–3432. https://doi.org/10.1002/art.21391
doi: 10.1002/art.21391
Balandraud N, Auger I, Roudier J (2021) Do RA associated HLA-DR molecules bind citrullinated peptides or peptides from PAD4 to help the development of RA specific antibodies to citrullinated proteins? J Autoimmun 116:102542. https://doi.org/10.1016/j.jaut.2020.102542
doi: 10.1016/j.jaut.2020.102542
Auger I, Balandraud N, Massy E, Hemon MF, Peen E, Arnoux F, Mariot C, Martin M, Lafforgue P, Busnel JM, Roudier J (2020) Peptidylarginine deiminase autoimmunity and the development of anti–citrullinated protein antibody in rheumatoid arthritis: the Hapten-Carrier model. Arthritis Rheumatol 72:903–911. https://doi.org/10.1002/art.41189
doi: 10.1002/art.41189
Kolfenbach JR, Deane KD, Derber LA, O’Donnell CI, Gilliland WR, Edison JD, Rosen A, Darrah E, Norris JM, Holers VM (2010) Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum 62:2633–2639. https://doi.org/10.1002/art.27570
doi: 10.1002/art.27570
Begovich AB, Carlton VEH, Honigberg LA et al (2004) A missense single-nucleotide polymorphism in a gene encoding a proteintyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 75:330–337. https://doi.org/10.1086/422827
doi: 10.1086/422827
Klareskog L, Malmström V, Lundberg K, Padyukov L, Alfredsson L (2011) Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol 23:92–98. https://doi.org/10.1016/j.smim.2011.01.014
doi: 10.1016/j.smim.2011.01.014
Källberg H, Ding B, Padyukov L et al (2011) Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 70:508–511. https://doi.org/10.1136/ard.2009.120899
doi: 10.1136/ard.2009.120899
Linn-Rasker SP, Van Der Helm-Van Mil AHM, Van Gaalen FA, Kloppenburg M, De Vries RRP, Le Cessie S, Breedveld FC, Toes REM, Huizinga TWJ (2006) Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 65:366–371. https://doi.org/10.1136/ard.2005.041079
doi: 10.1136/ard.2005.041079
van Wesemael TJ, Ajeganova S, Humphreys J et al (2016) Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: A multicenter cohort study. Arthritis Res Ther 18:1–10. https://doi.org/10.1186/s13075-016-1177-9
doi: 10.1186/s13075-016-1177-9
Roos Ljungberg K, Börjesson E, Martinsson K, Wetterö J, Kastbom A, Svärd A (2020) Presence of salivary IgA anti-citrullinated protein antibodies associate with higher disease activity in patients with rheumatoid arthritis. Arthritis Res Ther 22:1–10. https://doi.org/10.1186/s13075-020-02363-0
doi: 10.1186/s13075-020-02363-0
Llorente I, Merino L, Ortiz AM, Escolano E, González-Ortega S, García-Vicuña R, García-Vadillo JA, Castañeda S, González-Álvaro I (2017) Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients. Rheumatol Int 37:799–806. https://doi.org/10.1007/s00296-017-3674-9
doi: 10.1007/s00296-017-3674-9
Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, Rönnelid J, Harris HE, Ulfgren AK, Rantapää-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L (2006) A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 54:38–46. https://doi.org/10.1002/art.21575
doi: 10.1002/art.21575
Mercado F, Marshall RI, Klestov AC, Bartold PM (2000) Is there a relationship between rheumatoid arthritis and periodontal disease? J Clin Periodontol 27:267–272. https://doi.org/10.1034/j.1600-051x.2000.027004267.x
doi: 10.1034/j.1600-051x.2000.027004267.x
Mikuls TR, Payne JB, Yu F, Thiele GM, Reynolds RJ, Cannon GW, Markt J, McGowan D, Kerr GS, Redman RS, Reimold A, Griffiths G, Beatty M, Gonzalez SM, Bergman DA, Hamilton BC, Erickson AR, Sokolove J, Robinson WH, Walker C, Chandad F, O’Dell JR (2014) Periodontitis and porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol 66:1090–1100. https://doi.org/10.1002/art.38348
doi: 10.1002/art.38348
Hitchon CA, Chandad F, Ferucci ED, Willemze A, Ioan-Facsinay A, Van Der Woude D, Markland J, Robinson D, Elias B, Newkirk M, Toes RM, Huizinga TWJ, El-Gabalawy HS (2010) Antibodies to Porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. J Rheumatol 37:1105–1112. https://doi.org/10.3899/jrheum.091323
doi: 10.3899/jrheum.091323
Bae SC, Lee YH (2018) Association between anti-Porphyromonas gingivalis antibody, anti-citrullinated protein antibodies, and rheumatoid arthritis: a meta-analysis. Z Rheumatol 77:522–532. https://doi.org/10.1007/s00393-017-0328-y
doi: 10.1007/s00393-017-0328-y
Laugisch O, Wong A, Sroka A, Kantyka T, Koziel J, Neuhaus K, Sculean A, Venables PJ, Potempa J, Möller B, Eick S (2016) Citrullination in the periodontium—a possible link between periodontitis and rheumatoid arthritis. Clin Oral Investig 20:675–683. https://doi.org/10.1007/s00784-015-1556-7
doi: 10.1007/s00784-015-1556-7
Loutan L, Alpizar-Rodriguez D, Courvoisier DS, Finckh A, Mombelli A, Giannopoulou C (2019) Periodontal status correlates with anti-citrullinated protein antibodies in first-degree relatives of individuals with rheumatoid arthritis. J Clin Periodontol 46:690–698. https://doi.org/10.1111/jcpe.13117
doi: 10.1111/jcpe.13117
Mikuls TR, Thiele GM, Deane KD, Payne JB, O’Dell JR, Yu F, Sayles H, Weisman MH, Gregersen PK, Buckner JH, Keating RM, Derber LA, Robinson WH, Holers VM, Norris JM (2012) Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum 64:3522–3530. https://doi.org/10.1002/art.34595
doi: 10.1002/art.34595
Sakkas LI, Daoussis D, Liossis SN, Bogdanos DP (2017) The infectious basis of ACPA-positive rheumatoid arthritis. Front Microbiol 8:1–9. https://doi.org/10.3389/fmicb.2017.01853
doi: 10.3389/fmicb.2017.01853
Konig MF, Abusleme L, Reinholdt J, Palmer RJ, Teles RP, Sampson K, Rosen A, Nigrovic PA, Sokolove J, Giles JT, Moutsopoulos NM, Andrade F (2016) Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. Sci Transl Med 8:1–13. https://doi.org/10.1126/scitranslmed.aaj1921
doi: 10.1126/scitranslmed.aaj1921
Giles JT, Reinholdt J, Andrade F, Konig MF (2021) Associations of antibodies targeting periodontal pathogens with subclinical coronary, carotid, and peripheral arterial atherosclerosis in rheumatoid arthritis. Arthritis Rheumatol 73:568–575. https://doi.org/10.1002/art.41572
doi: 10.1002/art.41572
Vossenaar ER, Smeets TJM, Kraan MC, Raats JM, Van Venrooij WJ, Tak PP (2004) The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 50:3485–3494. https://doi.org/10.1002/art.20584
doi: 10.1002/art.20584
Masson-Bessière C, Sebbag M, Durieux JJ, Nogueira L, Vincent C, Girbal-Neuhauser E, Durroux R, Cantagrel A, Serre G (2000) In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 119:544–552. https://doi.org/10.1046/j.1365-2249.2000.01171.x
doi: 10.1046/j.1365-2249.2000.01171.x
Makrygiannakis D, Af Klint E, Lundberg IE, Löfberg R, Ulfgren AK, Klareskog L, Catrina AI (2006) Citrullination is an inflammation-dependent process. Ann Rheum Dis 65:1219–1222. https://doi.org/10.1136/ard.2005.049403
doi: 10.1136/ard.2005.049403
Turunen S, Huhtakangas J, Nousiainen T, Valkealahti M, Melkko J, Risteli J, Lehenkari P (2016) Rheumatoid arthritis antigens homocitrulline and citrulline are generated by local myeloperoxidase and peptidyl arginine deiminases 2, 3 and 4 in rheumatoid nodule and synovial tissue. Arthritis Res Ther 18:1–15. https://doi.org/10.1186/s13075-016-1140-9
doi: 10.1186/s13075-016-1140-9
Vossenaar ER, Nijenhuis S, Helsen MMA, Van der Heijden A, Senshu T, Van den Berg WB, Van Venrooij WJ, Joosten LAB (2003) Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 48:2489–2500. https://doi.org/10.1002/art.11229
doi: 10.1002/art.11229
Foulquier C, Sebbag M, Clavel C, Chapuy-Regaud S, Al Badine R, Méchin MC, Vincent C, Nachat R, Yamada M, Takahara H, Simon M, Guerrin M, Serre G (2007) Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 56:3541–3553. https://doi.org/10.1002/art.22983
doi: 10.1002/art.22983
Kleyer A, Finzel S, Rech J, Manger B, Krieter M, Faustini F, Araujo E, Hueber AJ, Harre U, Engelke K, Schett G (2014) Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis 73:854–860. https://doi.org/10.1136/annrheumdis-2012-202958
doi: 10.1136/annrheumdis-2012-202958
Hafström I, Ajeganova S, Forslind K, Svensson B (2019) Anti-citrullinated protein antibodies are associated with osteopenia but not with pain at diagnosis of rheumatoid arthritis: Data from the BARFOT cohort. Arthritis Res Ther 21:1–9. https://doi.org/10.1186/s13075-019-1833-y
doi: 10.1186/s13075-019-1833-y
De Punder YMR, Hendrikx J, Den Broeder AA, Pascual EV, Van Riel PL, Fransen J (2013) Should we redefine treatment targets in rheumatoid arthritis? Low disease activity is sufficiently strict for patients who are anticitrullinated protein antibody-negative. J Rheumatol 40:1268–1274. https://doi.org/10.3899/jrheum.121438
doi: 10.3899/jrheum.121438
Ajeganova S, Huizinga TWJ (2015) Seronegative and seropositive RA: alike but different? Nat Rev Rheumatol 11:8–9. https://doi.org/10.1038/nrrheum.2014.194
doi: 10.1038/nrrheum.2014.194
Barra L, Pope JE, Orav JE, Boire G, Haraoui B, Hitchon C, Keystone EC, Thorne JC, Tin D, Bykerk VP (2014) Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. J Rheumatol 41:2361–2369. https://doi.org/10.3899/jrheum.140082
doi: 10.3899/jrheum.140082
Nijjar JS, Morton FR, Bang H et al (2021) The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study. Lancet Rheumatol 3:284–293. https://doi.org/10.1016/S2665-9913(20)30381-7
doi: 10.1016/S2665-9913(20)30381-7
Hecht C, Englbrecht M, Rech J, Schmidt S, Araujo E, Engelke K, Finzel S, Schett G (2015) Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis 74:2151–2156. https://doi.org/10.1136/annrheumdis-2014-205428
doi: 10.1136/annrheumdis-2014-205428
Bugatti S, Bogliolo L, Vitolo B, Manzo A, Montecucco C, Caporali R (2016) Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Res Ther 18:1–8. https://doi.org/10.1186/s13075-016-1116-9
doi: 10.1186/s13075-016-1116-9
Ince-Askan H, Dolhain RJEM (2015) Pregnancy and rheumatoid arthritis. Best Pract Res Clin Rheumatol 29:580–596. https://doi.org/10.1016/j.berh.2015.07.001
doi: 10.1016/j.berh.2015.07.001
Hensvold AH, Frisell T, Magnusson PKE, Holmdahl R, Askling J, Catrina AI (2017) How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins. Ann Rheum Dis 76:119–125. https://doi.org/10.1136/annrheumdis-2015-208980
doi: 10.1136/annrheumdis-2015-208980
Nielen MMJ, Van Schaardenburg D, Reesink HW, Van De Stadt RJ, Van Der Horst-Bruinsma IE, De Koning MHMT, Habibuw MR, Vandenbroucke JP, Dijkmans BAC (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386. https://doi.org/10.1002/art.20018
doi: 10.1002/art.20018
Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, Jakobsson PJ, Baum W, Nimmerjahn F, Szarka E, Sarmay G, Krumbholz G, Neumann E, Toes R, Scherer HU, Catrina AI, Klareskog L, Jurdic P, Schett G (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791–1802. https://doi.org/10.1172/JCI60975
doi: 10.1172/JCI60975
Kurowska W, Slowinska I, Krogulec Z, Syrowka P, Maslinski W (2021) Antibodies to citrullinated Proteins ( ACPA ) associate with markers of osteoclast activation and bone destruction in the bone marrow of patients with rheumatoid arthritis. J Clin Med 10:1778. https://doi.org/10.3390/jcm10081778
doi: 10.3390/jcm10081778
Laurent L, Anquetil F, Clavel C, Ndongo-Thiam N, Offer G, Miossec P, Pasquali JL, Sebbag M, Serre G (2015) IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies. Ann Rheum Dis 74:1425–1431. https://doi.org/10.1136/annrheumdis-2013-204543
doi: 10.1136/annrheumdis-2013-204543
Dong X, Zheng Z, Lin P, Fu X, Li F, Jiang J, Zhu P (2020) ACPAs promote IL-1β production in rheumatoid arthritis by activating the NLRP3 inflammasome. Cell Mol Immunol 17:261–271. https://doi.org/10.1038/s41423-019-0201-9
doi: 10.1038/s41423-019-0201-9
Sun M, Rethi B, Krishnamurthy A, Joshua V, Circiumaru A, Hensvold AH, Ossipova E, Grönwall C, Liu Y, Engstrom M, Catrina SB, Steen J, Malmstrom V, Klareskog L, Svensson C, Ospelt C, Wähämaa H, Catrina AI (2019) Anticitrullinated protein antibodies facilitate migration of synovial tissue-derived fibroblasts. Ann Rheum Dis 78:1621–1631. https://doi.org/10.1136/annrheumdis-2018-214967
doi: 10.1136/annrheumdis-2018-214967
Wigerblad G, Bas DB, Fernandes-Cerqueira C (2019) Correction: Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann Rheum Dis (2016) 75(730). https://doi.org/10.1136/annrheumdis-2015-208094 . Ann Rheum Dis 78:865. https://doi.org/10.1136/annrheumdis-2015-208094corr1
O’Neil LJ, Barrera-Vargas A, Sandoval-Heglund D, Merayo-Chalico J, Aguirre-Aguilar E, Aponte AM, Ruiz-Perdomo Y, Gucek M, El-Gabalawy H, Fox DA, Katz JD, Kaplan MJ, Carmona-Rivera C (2020) Neutrophil-mediated carbamylation promotes articular damage in rheumatoid arthritis. Sci Adv 6:1–16. https://doi.org/10.1126/sciadv.abd2688
doi: 10.1126/sciadv.abd2688
Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, Holers VM (2006) Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 116:961–973. https://doi.org/10.1172/JCI25422
doi: 10.1172/JCI25422
Dusad A, Duryee MJ, Shaw AT, Klassen LW, Anderson DR, Wang D, Ren K, Gravallese EM, O’Dell JR, Mikuls TR, Thiele GM (2014) Induction of bone loss in DBA/1J mice immunized with citrullinated autologous mouse type II collagen in the absence of adjuvant. Immunol Res 58:51–60. https://doi.org/10.1007/s12026-013-8479-7
doi: 10.1007/s12026-013-8479-7
Cantaert T, Teitsma C, Tak PP, Baeten D (2013) Presence and role of anti-citrullinated protein antibodies in experimental arthritis models. Arthritis Rheum 65:939–948. https://doi.org/10.1002/art.37839
doi: 10.1002/art.37839
Böhm S, Schwab I, Lux A, Nimmerjahn F (2012) The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol 34:443–453. https://doi.org/10.1007/s00281-012-0308-x
doi: 10.1007/s00281-012-0308-x
Sehic E, Westerlund A, Lagerquist MK, Lerner UH, Carlsten H, Henning P, Engdahl C (2021) Immunoglobulin G complexes without sialic acids enhance osteoclastogenesis but do not affect arthritis-mediated bone loss. Scand J Immunol 93:1–11. https://doi.org/10.1111/sji.13009
doi: 10.1111/sji.13009
Harre U, Lang SC, Pfeifle R, Rombouts Y, Frühbeißer S, Amara K, Bang H, Lux A, Koeleman CA, Baum W, Dietel K, Gröhn F, Malmström V, Klareskog L, Krönke G, Kocijan R, Nimmerjahn F, Toes REM, Herrmann M, Scherer HU, Schett G (2015) Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun 6:6651. https://doi.org/10.1038/ncomms7651
doi: 10.1038/ncomms7651
Pfeifle R, Rothe T, Ipseiz N et al (2017) Regulation of autoantibody activity by the IL-23-T H 17 axis determines the onset of autoimmune disease. Nat Immunol 18:104–113. https://doi.org/10.1038/ni.3579
doi: 10.1038/ni.3579
Scherer HU, Van Der Woude D, Ioan-Facsinay A, El Bannoudi H, Trouw LA, Wang J, Häupl T, Burmester GR, Deelder AM, Huizinga TWJ, Wuhrer M, Toes REM (2010) Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 62:1620–1629. https://doi.org/10.1002/art.27414
doi: 10.1002/art.27414
Vergroesen RD, Slot LM, Hafkenscheid L, Koning MT, Van Der Voort EIH, Grooff CA, Zervakis G, Veelken H, Huizinga TWJ, Rispens T, Scherer HU, Toes REM (2018) B-cell receptor sequencing of anti-citrullinated protein antibody (ACPA) IgG-expressing B cells indicates a selective advantage for the introduction of N-glycosylation sites during somatic hypermutation. Ann Rheum Dis 77:955–957. https://doi.org/10.1136/annrheumdis-2017-212052
doi: 10.1136/annrheumdis-2017-212052
Rombouts Y, Willemze A, Van Beers JJBC et al (2016) Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Ann Rheum Dis 75:578–585. https://doi.org/10.1136/annrheumdis-2014-206598
doi: 10.1136/annrheumdis-2014-206598
Corsiero E, Carlotti E, Jagemann L, Perretti M, Pitzalis C, Bombardieri M (2020) H and L chain affinity maturation and/or Fab N-glycosylation influence immunoreactivity toward neutrophil extracellular trap antigens in rheumatoid arthritis synovial B cell clones. J Immunol 204:2374–2379. https://doi.org/10.4049/jimmunol.1901457
doi: 10.4049/jimmunol.1901457
Kempers AC, Hafkenscheid L, Dorjée AL, Moutousidou E, Van De Bovenkamp FS, Rispens T, Trouw LA, Van Oosterhout M, Huizinga TWJ, Toes R, Scherer HU (2018) The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM. Ann Rheum Dis 77:1087–1088. https://doi.org/10.1136/annrheumdis-2017-211533
doi: 10.1136/annrheumdis-2017-211533
Vergroesen RD, Slot LM, van Schaik BDC, Koning MT, Rispens T, van Kampen AHC, Toes REM, Scherer HU (2019) N-glycosylation site analysis of citrullinated antigen-specific B-cell receptors indicates alternative selection pathways during autoreactive B-cell development. Front Immunol 10:2092. https://doi.org/10.3389/fimmu.2019.02092
doi: 10.3389/fimmu.2019.02092
Suwannalai P, Britsemmer K, Knevel R, Scherer HU, Levarht EWN, Van Der Helm-Van Mil AH, Van Schaardenburg D, Huizinga TWJ, Toes REM, Trouw LA (2014) Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis 73:270–276. https://doi.org/10.1136/annrheumdis-2012-202615
doi: 10.1136/annrheumdis-2012-202615
Van Zanten A, Arends S, Roozendaal C, Limburg PC, Maas F, Trouw LA, Toes REM, Huizinga TWJ, Bootsma H, Brouwer E (2017) Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. Ann Rheum Dis 76:1184–1190. https://doi.org/10.1136/annrheumdis-2016-209991
doi: 10.1136/annrheumdis-2016-209991
Shi J, van de Stadt LA, Levarht EWN, Huizinga TWJ, Hamann D, van Schaardenburg D, Toes REM, Trouw LA (2014) Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis 73:780–783. https://doi.org/10.1136/annrheumdis-2013-204154
doi: 10.1136/annrheumdis-2013-204154
Van Der Woude D, Rantapää-Dahlqvist S, Ioan-Facsinay A, Onnekink C, Schwarte CM, Verpoort KN, Drijfhout JW, Huizinga TWJ, Toes REM, Pruijn GJM (2010) Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 69:1554–1561. https://doi.org/10.1136/ard.2009.124537
doi: 10.1136/ard.2009.124537
ten Brinck RM, van Steenbergen HW, van Delft MAM, Verheul MK, Toes REM, Trouw LA, van der Helm-van Mil AHM (2017) The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia. Rheumatology (Oxford) 56:2145–2153. https://doi.org/10.1093/rheumatology/kex340
doi: 10.1093/rheumatology/kex340
Mankia K, D’Agostino MA, Rowbotham E, Hensor EMA, Hunt L, Möller I, Miguel M, Mérida-Velasco JR, Murillo-González J, Naredo E, Nam JL, Tan AL, Freeston JE, Grainger A, Emery P (2019) MRI inflammation of the hand interosseous tendons occurs in anti-CCP-positive at-risk individuals and may precede the development of clinical synovitis. Ann Rheum Dis 78:781–786. https://doi.org/10.1136/annrheumdis-2018-214331
doi: 10.1136/annrheumdis-2018-214331
Ford JA, Liu X, Marshall AA, Zaccardelli A, Prado MG, Wiyarand C, Lu B, Karlson EW, Schur PH, Deane KD, Sparks JA (2019) Impact of cyclic citrullinated peptide antibody level on progression to rheumatoid arthritis in clinically tested cyclic citrullinated peptide antibody–positive patients without rheumatoid arthritis. Arthritis Care Res 71:1583–1592. https://doi.org/10.1002/acr.23820
doi: 10.1002/acr.23820
Bemis EA, Demoruelle MK, Seifert JA, Polinski KJ, Weisman MH, Buckner JH, Gregersen PK, Mikuls TR, Odell JR, Keating RM, Deane KD, Holers VM, Norris JM (2021) Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting. Ann Rheum Dis 80:154–161. https://doi.org/10.1136/annrheumdis-2020-217066
doi: 10.1136/annrheumdis-2020-217066
Finckh A, Courvoisier D, Lamacchia C (2020) Measuring ACPA in the general population or primary care: Is it useful? RMD Open 6:1–7. https://doi.org/10.1136/rmdopen-2019-001085
doi: 10.1136/rmdopen-2019-001085
Rombouts Y, Ewing E, Van De Stadt LA, Selman MHJ, Trouw LA, Deelder AM, Huizinga TWJ, Wuhrer M, Van Schaardenburg D, Toes REM, Scherer HU (2015) Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis 74:234–241. https://doi.org/10.1136/annrheumdis-2013-203565
doi: 10.1136/annrheumdis-2013-203565
Verpoort KN, Jol-Van Der Zijde CM, Papendrecht-Van Der Voort EAM, Ioan-Facsinay A, Drijfhout JW, Van Tol MJD, Breedveld FC, Huizinga TWJ, Toes REM (2006) Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 54:3799–3808. https://doi.org/10.1002/art.22279
doi: 10.1002/art.22279
de Moel EC, Derksen VFAM, Stoeken G, Trouw LA, Bang H, Goekoop RJ, Speyer I, Huizinga TWJ, Allaart CF, Toes REM, van der Woude D (2018) Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes. Arthritis Res Ther 20:1–12. https://doi.org/10.1186/s13075-018-1520-4
doi: 10.1186/s13075-018-1520-4
Figueiredo CP, Bang H, Cobra JF et al (2017) Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs. Ann Rheum Dis 76:399–407. https://doi.org/10.1136/annrheumdis-2016-209297
doi: 10.1136/annrheumdis-2016-209297
De Moel EC, Derksen VFAM, Trouw LA, Bang H, Collée G, Lard LR, Ramiro S, Huizinga TWJ, Allaart CF, Toes REM, Van Der Woude D (2019) In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Res Ther 21:1–8. https://doi.org/10.1186/s13075-019-1815-0
doi: 10.1186/s13075-019-1815-0
Pyrpasopoulou A, Douma S, Triantafyllou A, Simoulidou E, Samara M, Parapanisiou E, Aslanidis S (2010) Response to Rituximab and Timeframe to Relapse in Rheumatoid Arthritis Patients. Mol Diagn Ther 14:43–48. https://doi.org/10.1007/BF03256352
doi: 10.1007/BF03256352
Alemao E, Postema R, Elbez Y, Mamane C, Finckh A (2020) Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol 38:455–466
Courvoisier DS, Chatzidionysiou K, Mongin D et al (2021) The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology (Oxford) 60:820–828. https://doi.org/10.1093/rheumatology/keaa393
doi: 10.1093/rheumatology/keaa393
Bird P, Hall S, Nash P, Connell CA, Kwok K, Witcombe D, Thirunavukkarasu K (2019) Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. RMD Open 5:e000742. https://doi.org/10.1136/rmdopen-2018-000742
doi: 10.1136/rmdopen-2018-000742
Lamacchia C, Courvoisier DS, Jarlborg M, Bas S, Roux-Lombard P, Möller B, Ciurea A, Finckh A, Bentow C, Martinez-Prat L, Mahler M, Gabay C, Nissen MJ (2021) Predictive value of anti-CarP and anti-PAD3 antibodies alone or in combination with RF and ACPA on the severity of rheumatoid arthritis. Rheumatology (Oxford) keab050. https://doi.org/10.1093/rheumatology/keab050
Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, Rantapää-Dahlqvist S (2006) Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 65:453–458. https://doi.org/10.1136/ard.2005.041376
doi: 10.1136/ard.2005.041376
Fedele AL, Petricca L, Tolusso B, Alivernini S, Canestri S, Di Mario C, Bosello SL, Ferraccioli G, Gremese E (2018) Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy. Scand J Rheumatol 47:351–359. https://doi.org/10.1080/03009742.2017.1416668
doi: 10.1080/03009742.2017.1416668
Myasoedova E, Davis J, Matteson EL, Crowson CS (2020) Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014. Ann Rheum Dis 79:440–444. https://doi.org/10.1136/annrheumdis-2019-216694
doi: 10.1136/annrheumdis-2019-216694
Paalanen K, Puolakka K, Nikiphorou E, Hannonen P, Sokka T (2021) Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study. Rheumatology (Oxford) 60:2391–2395. https://doi.org/10.1093/rheumatology/keaa623
doi: 10.1093/rheumatology/keaa623
Paalanen K, Rannio K, Rannio T, Asikainen J, Hannonen P, Sokka T (2019) Does early seronegative arthritis develop into rheumatoid arthritis? A 10-year observational study. Clin Exp Rheumatol 37:37–43
Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808. https://doi.org/10.7326/0003-4819-146-11-200706050-00008
doi: 10.7326/0003-4819-146-11-200706050-00008
Pecani A, Alessandri C, Spinelli FR, Priori R, Riccieri V, Di Franco M, Ceccarelli F, Colasanti T, Pendolino M, Mancini R, Truglia S, Barbati C, Vomero M, Sabatinelli D, Morello F, Valesini G, Conti F (2016) Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases. Arthritis Res Ther 18:1–8. https://doi.org/10.1186/s13075-016-1173-0
doi: 10.1186/s13075-016-1173-0
Sidiras P, Spruyt D, Gangji V, Imbault V, Sokolova T, Durez P, Communi D, Rasschaert J, Badot V (2021) Antibodies against carbamylated proteins: prevalence and associated disease characteristics in Belgian patients with rheumatoid arthritis or other rheumatic diseases. Scand J Rheumatol 50:118–123. https://doi.org/10.1080/03009742.2020.1798500
doi: 10.1080/03009742.2020.1798500
Kolarz B, Ciesla M, Rosenthal AK, Dryglewska M, Majdan M (2021) The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA/RF negative rheumatoid arthritis patients. Ther Adv Musculoskelet Dis 13:1–10. https://doi.org/10.1177/1759720X21989868
doi: 10.1177/1759720X21989868